Brought to you by 
SDP exercises option to acquire five Roivant divisions; forms Sumitovant to run them
25 Oct 2022
Executive Summary
| Sumitomo Dainippon Pharma Co. Ltd. (SDP) paid $3bn in cash to exercise its previously announced option to acquire five Roivant Sciences Inc. biopharmaceutical divisions (known as vants). The five companies--Altavant Sciences Inc. (rare respiratory diseases), Enzyvant Sciences Ltd. (rare immunodeficiency diseases), Myovant Sciences Ltd. (women's health and prostate cancer), Urovant Sciences Ltd. (urinary disorders), and Spirovant Sciences Ltd. (gene therapies for cystic fibrosis)--will operate under a newly formed, 50.2% wholly owned SDP subsidiary Sumitovant Biopharma Ltd., run by Roivant's Myrtle Potter as CEO. |
Deal Industry
- Pharmaceuticals
-
Pharmaceuticals
- Specialty Pharmaceuticals
-
Biotechnology
- Antisense, Oligonucleotides
- Gene Therapy, Cell Therapy
Deal Status
- Final
Deal Type
-
Acquisition
- Acquisition of Private Biotech
- Full Acquisition
- Payment Includes Cash for Equity
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
SDP exercises option to acquire five Roivant divisions; forms Sumitovant to run them
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice